The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Thu, 01st Apr 2021 12:00

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based live biotherapeutic products developer - Posts pretax loss of GBP30.3 million in 2020, widening from GBP29.0 million a year prior. Revenue more-than-doubles to GBP534,000 from GBP211,000. Administrative expenses double to GBP9.1 million from GBP4.4 million. "4D has made significant progress leading the field in the development of live biotherapeutics, and made great strides from a corporate perspective. In addition to the data we have generated in the field of oncology, we completed our merger with Longevity and obtained a NASDAQ listing which, together with a concurrent fundraise, provides 4D with approximately USD40 million of additional capital and a solid financial footing moving forward. This puts 4D pharma in a strong position to capitalise on multiple data readouts from our ongoing trials in asthma and oncology as well as facilitating the move into the clinic with our Parkinson's disease programme," says 4D Pharma.

----------

Sportech PLC - Edinburgh-based gambling technology firm - Posts pretax loss from continuing operations for 2020 of GBP10.6 million, widening 9.3% from GBP9.7 million a year prior. Revenue sinks to GBP20.0 million from GBP33.6 million. "Providing a long-term projection with any degree of certainty in this environment is challenging and unrealistic, however having negotiated several corporate transactions during the last 12 months, when completed, the group will have reduced investors' risk and simplified the structure and the opportunities ahead," says Sportech.

----------

BSF Enterprise PLC - UK-based company formed to undertake an acquisition - Posts pretax loss of GBP93,845 in the year ended September 30, 2020, narrowed from GBP94,398 a year prior. "In the context of this challenging capital raising environment during this Covid-19 pandemic, I believe that BSF represents an extremely attractive proposition to prospective acquisition counterparties considering listing on the London Stock Exchange and I remain confident that we will be able to execute an acquisition that creates value for our shareholders," says BSF.

----------

Nippon Active Value Fund PLC - Japan-focused investment firm - Posts net asset value per share at December 30 of 113.58 pence, in its annual report for the period from incorporation on October 22, 2019 to December 30, 2020. NAV per share increases 14% since IPO. Declares inaugural dividend of 0.85p per share. Says it will not target a dividend for future years but will substantially pay out distributable income for any particular period by way of dividend.

----------

Syncona Ltd - investor in life science companies - Notes results of portfolio company and biotechnology firm Freeline Therapeutics Holdings PLC. Freeline posts pretax loss for 2020 of USD96.2 million, widening from USD53.8 million a year prior. Research & development costs increase to USD76.1 million from USD47.0 million. "We are pleased with our current progress and aim to have three Freeline programs in the clinic by the end of 2021," said Theresa Heggie, Chief Executive Officer of Freeline.

----------

Horizonte Minerals PLC - nickel company focused on Brazil - Posts pretax loss of GBP2.6 million in 2020, widening 13% from GBP2.3 million a year prior. Administrative expenses increase to GBP2.9 million from GBP2.6 million. Says assets are not generating revenues. Does not declare any dividend in 2020, unchanged from a year prior. "The Covid-19 pandemic was unfortunately not an isolated event in 2020, it has continued in to 2021 and we will continue to feel its effects well into the medium term. However, with the accelerating rollout of a number of vaccines we are hopeful for a more certain, less interrupted year in 2021," says Horizonte.

----------

Proteome Sciences PLC - drug development services provider - Posts pretax profit of GBP245,000 in 2020, swinging from a loss of GBP36,000 a year before. Revenue increases to GBP4.8 million from GBP4.7 million. Administrative expenses fall 25% to GBP2.0 million from GBP2.7 million. "We have started an internal analysis on growing our business further in addition to our current activities. We believe that with our specialist expertise the market for our niche services has the potential to grow substantially as proteomics plays an increasingly vital role in drug discovery, development and in the response to current and future medical challenges," says Proteome.

----------

Arbuthnot Banking Group PLC - London-based private and commercial banking - Says subsidiary Arbuthnot Latham completes acquisition of provider of vehicle finance Asset Alliance Group Holdings Ltd. Says the consideration is now anticipated to be approximately GBP10.1 million.

----------

Stanley Gibbons Group PLC - London-based collectible postage stamp retailer - Says it has seen increased levels of digital activity and remote selling of albums and accessories contrasting with lower levels of high ticket sales and in person activities as a result of the third lockdown throughout the year to March 31. Says second half trading was better than the first. "We are hopeful that a vaccine led relaxing of restrictions is not only permanent but encourages activity levels to return at pace, however, this is hard to predict and we have plans in place if this is not how things develop," says Stanley Gibbons.

----------

Great Western Mining Corp PLC - mineral exploration and development company with gold, silver and copper assets in the US - Says drilling has start in Nevada to test a prospective copper target and is likely to be followed by a second hole on the same prospect. "This is an exciting moment for the company, being the first time in its history that it has launched a major drilling campaign for precious metals, while a recent fund-raising will enable us to expand the programme where appropriate," says Chair Brian Hall.

----------

Macfarlane Group PLC - Glasgow-based packaging firm - Announces acquisition of Carters Packaging Ltd in Cornwall. Carters is a distributor of protective packaging in the south-west of England. The acquisition will go for a maximum cash consideration of GBP4.5 million.

----------

1Spatial PLC - Cambridge-based location data software provider - Announces a multiyear contract with Defra to provide a managed service for Rural Payments Agency's Customer Portal and Land Management System. The total potential contract value over five years for 1Spatial is in excess of GBP900,000. The first three years will net the company GBP600,000, or GBP200,000 a year, while Defra has an option to extend for a further two years for GBP300,000.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jul 2020 14:39

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

Read more
6 Jul 2020 12:38

Next part of tumour trial begins for 4D Pharma

(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.

Read more
6 Jul 2020 10:17

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

Read more
2 Jul 2020 12:14

Patient enrolment begins for 4D's Covid therapy candidate

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.

Read more
2 Jul 2020 09:16

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

Read more
26 May 2020 10:06

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

Read more
11 May 2020 10:45

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

Read more
20 Apr 2020 11:08

4D Pharma receives expedited approval for coronavirus study

(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.

Read more
20 Apr 2020 10:30

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

Read more
17 Apr 2020 13:53

4D Pharma upbeat on key findings from Blautix study

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.

Read more
17 Apr 2020 10:14

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

Read more
18 Mar 2020 18:09

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

Read more
18 Feb 2020 18:44

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

Read more
18 Feb 2020 09:26

4D Pharma raising at least ?18m via placing and subscription

(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.

Read more
18 Feb 2020 09:03

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.